Jane Holmes Hollingsworth is managing partner of Militia Hill Ventures, a business focused on building and growing high quality life sciences companies, and executive chair of Talee Bio, a gene therapy company with a focus on cystic fibrosis and diseases of the lung. Jane is also former executive chair of Immunome Inc., a cancer immunotherapy company, and co-founder and former CEO of NuPathe Inc., a publicly traded biopharmaceutical company focused on diseases of the central nervous system, sold to Teva in 2014. Jane also co-founded and served as EVP of Auxilium Pharmaceuticals, a biopharmaceutical company focused on urology and sold to Endo in 2015.
Prior to launching and leading multiple successful biopharmaceutical companies, Ms. Hollingsworth was VP, secretary, and general counsel of IBAH, Inc., a publicly traded, multinational clinical research organization. Before joining IBAH, she practiced law at the Philadelphia law firm of Montgomery, McCracken, Walker & Rhoads and served as law clerk to the Honorable Jane R. Roth of the United States District Court for the District of Delaware.
Ms. Hollingsworth is one of the leaders of the entrepreneurial and life sciences communities and serves on various industry and community boards, including DS Biopharma, Talee Bio, the University City Science Center, the Kimmel Center for the Performing Arts, and Breastcancer.org.